Projects per year
Personal profile
Chinese Name
李敏
Biography
Professor Li Min is an expert in the treatment of neurodegenerative diseases by using Chinese medicine, a respected research scientist in the field of Autophagy, Chinese medicinal pharmacology in treating and prevention of Parkinson’s disease (PD), Alzheimer's disease (AD) and Amyotrophic Lateral Sclerosis (ALS). Currently, Professor Li holds these positions in the School of Chinese Medicine (SCM) at Hong Kong Baptist University (HKBU): Associate Dean of SCM; Programme Director of Bachelor of Chinese Medicine & Bachelor of Science (Hons) in Biomedical Science; Director, Master of Chinese Medicine programme; and Director, Mr. and Mrs. Ko Chi Ming Centre for Parkinson's Disease Research (CPDR).
Professor Li obtained her Bachelor's degree in Chinese Medicine from Henan University of Traditional Chinese Medicine (TCM), China, in 1985, she also obtained MPhil degree in Chinese Medicine at the Guangzhou University of Chinese Medicine, China, in 1988 and obtained her PhD degree in Cardiology at the School of Medicine, Tokai University, Japan, in 2001. Professor Li joined the SCM, HKBU in 2001 as assistant professor, her research focuses on neurodegenerative diseases, including Parkinson's disease (PD), Alzheimer's disease (AD) and vascular dementia (VD), as well as on cardio-cerebrovascular disease and on related new drug discovery. For more information please refer to her lab: https://cpdr.hkbu.edu.hk
As of March 2023, Professor Li has registered over 20 patents, and presented and/or published over 400 papers in journals, books and international conferences. Based on her outstanding research and clinical experience, Prof. Li received an Award of the Distinguished Female Chinese Medicine Practitioner by the China Association of Chinese medicine in 2007, School's Award for Outstanding Performance in Scholarly Work in 2012 and President's Award for Outstanding Performance in Teaching from Hong Kong Baptist University in 2013 and 2018. Prof. Li's clinical specialty is in Chinese medicine treatment of neurodegenerative diseases, including Parkinson's disease (PD), Alzheimer's disease (AD) and vascular dementia (VD), as well as on Cardio-cerebrovascular diseases.
Research Interests
Prof. Li's long-term research interests are:
- Neurodegenerative diseases including Parkinson's Disease (PD) , Alzheimer's Disease (AD) and Amyotrophic Lateral Sclerosis (ALS).
- Traditional Chinese medicine (TCM) for prevention and treatment of neurodegenerative diseases.
- Development of molecular targets for new drug discovery from TCM for neurodegenerative diseases.
Prof. Li's current research directions are:
- Autophagy regulation in neurodegenerative diseases including Alzheimer's disease (AD) , Parkinson's disease (PD) and Amyotrophic Lateral Sclerosis (ALS).
- Understanding the neuroprotective effects and underlying mechanisms of TCM on neurodegenerative diseases including AD, PD and ALS.
- Investigation of the efficacy and safety of TCM in the treatment of neurodegenerative diseases including AD and PD based on randomized controlled clinical trials, as well as the interaction of TCM and Western medicine.
Expertise related to UN Sustainable Development Goals
In 2015, UN member states agreed to 17 global Sustainable Development Goals (SDGs) to end poverty, protect the planet and ensure prosperity for all. This person’s work contributes towards the following SDG(s):
Education/Academic qualification
-, PhD, PhD Program in Medicine, School of Medicine, Tokai University, Japan
1 Apr 1998 → 23 Mar 2001
Award Date: 23 Mar 2001
Master, Master Program of Chinese Medicine, Guangzhou University of Chinese Medicine
1 Sept 1985 → 23 Jun 1988
Award Date: 23 Jun 1988
Bachelor, Bachelor Program of Chinese Medicine , Henan University of Chinese Medicine
1 Sept 1980 → 10 Jul 1985
Award Date: 10 Jul 1985
Keywords
- RZ Other systems of medicine
- Chinese medicine
- Neurodegenerative diseases
Fingerprint
Dive into the research topics where Min LI is active. Topic labels come from the works of this scholar.
- 1 Similar Scholars
Network
Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
-
Natural small molecule Isorhamnetin and its optimized derivatives for Parkinson's disease treatment by targeting TFEB-mediated autophagy.
1/12/22 → 30/11/25
Project: Research project
-
Evaluating the anti- Alzheimer' s efficacy of Caudatin, isolated from Chinese medicine herb Qingyangshen, on AD mice model
1/09/20 → 31/08/23
Project: Research project
-
-
-
Real-Time Detection and Visualization of Amyloid-β Aggregates Induced by Hydrogen Peroxide in Cell and Mouse Models of Alzheimer’s Disease
Wang, X., Iyaswamy, A., Xu, D., Krishnamoorthi, S., Sreenivasmurthy, S. G., Yang, Y., Li, Y., Chen, C., Li, M., Li, H-W. & Wong, M. S., 11 Jan 2023, In: ACS applied materials & interfaces. 15, 1, p. 39–47 9 p.Research output: Contribution to journal › Article › peer-review
Open Access14 Citations (Scopus) -
3-Acetylpyridine On-Tissue Paternò–Büchi Derivatization Enabling High Coverage Lipid C═C Location-Resolved MS Imaging in Biological Tissues
Chen, Y., Xie, C., Wang, X., Cao, G., Ru, Y., Song, Y., Iyaswamy, A., Li, M., Wang, J. & Cai, Z., 8 Nov 2022, In: Analytical Chemistry. 94, 44, p. 15367-15376 10 p.Research output: Contribution to journal › Article › peer-review
1 Citation (Scopus) -
A lymphatic route for a hyperbranched heteroglycan from Radix Astragali to trigger immune responses after oral dosing
Zhang, Q., Li, L., Hao, S., Liu, M., Huo, C., Wu, J., Liu, H., Bao, W., Zheng, H., Li, Z., Cheng, H., Fung, H., Wong, T., Leung, P., Wang, S., Li, T., Zhang, G., Li, M., Zhao, Z., Jia, W., & 6 others, 15 Sept 2022, In: Carbohydrate Polymers. 292, 12 p., 119653.Research output: Contribution to journal › Article › peer-review
Open Access2 Citations (Scopus) -
Alzheimer's Disease and other Tauopathies: Exploring Efficacy of Medicinal Plant-Derived Compounds in Alleviating Tau-Mediated Neurodegeneration
Durairajan, S. S. K., Selvarasu, K., Bera, M. R., Rajaram, K., Iyaswamy, A. & Li, M., Apr 2022, In: Current Molecular Pharmacology. 15, 2, p. 361-379 19 p.Research output: Contribution to journal › Review article › peer-review
14 Citations (Scopus) -
A novel DPP-4 inhibitor Gramcyclin A attenuates cognitive deficits in APP/PS1/tau triple transgenic mice via enhancing brain GLP-1-dependent glucose uptake
Li, Z., Zhang, Y., Meng, X., Li, M., Cao, W., Yang, J., Xu, X., Liu, W., Li, W., Cai, Q., Wang, S., Ma, G., Liu, Z. & Huang, G., Mar 2022, In: Phytotherapy Research. 36, 3, p. 1297-1309 13 p.Research output: Contribution to journal › Article › peer-review
4 Citations (Scopus)
Prizes
-
Best Poster Prize (“NRBF2 is involved in the degradation process of APP-CTFs in Alzheimer disease models”)
LI, Min (Recipient), 5 Sept 2017
Prize
-
Activities
-
Corynoxine has neuroprotective effects in experimental Alzheimer’s disease models via TFEB/TFE3-mediated autophagy induction
Min LI (Speaker)
26 Mar 2023 → 29 Mar 2023Activity: Conference/talk/lecture/symposium/speech/workshop, etc › Event organized by non-HKBU units
-
TFE3 deficiency aggravates tauopathy and impairs memory in mice involving CAPON accumulation
Min LI (Speaker)
26 Mar 2023 → 29 Mar 2023Activity: Conference/talk/lecture/symposium/speech/workshop, etc › Event organized by non-HKBU units
-
Studying the mechanism of (-)Schisandrin B on the treatment of Parkinson's disease via ATG16L1/NLRP3 signaling pathway
Min LI (Participant)
26 Mar 2023 → 29 Mar 2023Activity: Conference/talk/lecture/symposium/speech/workshop, etc › Event organized by non-HKBU units
-
The treatment of neurodegenerative diseases by Chinese herbal medicines: Targeting the autophagy-lysosome pathway
Min LI (Session chair)
27 Nov 2022Activity: Conference/talk/lecture/symposium/speech/workshop, etc › Event organized by non-HKBU units
-
Targeting autophagy for novel Chinese medicine development for Parkinson’s disease treatment
Min LI (Plenary/keynote speaker)
27 Aug 2022Activity: Conference/talk/lecture/symposium/speech/workshop, etc › Event organized by non-HKBU units